Positive status of alpha-fetoprotein and des-gamma-carboxy prothrombin: important prognostic factor for recurrent hepatocellular carcinoma - PubMed (original) (raw)

Positive status of alpha-fetoprotein and des-gamma-carboxy prothrombin: important prognostic factor for recurrent hepatocellular carcinoma

Masaki Kaibori et al. World J Surg. 2004 Jul.

Abstract

The aim of this study was to evaluate prognostic factors after the recurrence of hepatocellular carcinoma (HCC) in patients who had undergone hepatic resection. We used univariate and multivariate retrospective analyses of 29 clinicopathologic factors in 143 patients with recurrent HCC. Patients were classified into four groups according to the positivity of tumor markers at the time of recurrence. Survival rates and prognostic factors were then compared among the four groups. Multivariate analysis revealed four independent prognostic factors at recurrence: albumin level < 3.5 g/dl ( p = 0.0003), period until recurrence </= 1 year ( p = 0.0004), positive status of alpha-fetoprotein and des-gamma-carboxy prothrombin (AFP+/DCP+) ( p < 0.0001), and portal vein invasion ( p < 0.0001). Among groups with varying status of AFP/DCP, the survival rate in patients with AFP+/DCP+ at recurrence was significantly lower than those in the other three groups (+/+ 15.9% vs. +/- 47.2%, -/+ 44.8%, or -/- 61.1% at 3 years: p < 0.05). The AFP+/DCP+ group also had significantly higher rates of the recurrence appearing </= 1 year after operation (+/+ 68.3% vs. +/- 45.2%, -/+ 41.9%, or -/- 32.5%: p = 0.0108), extrahepatic recurrence (29.3% vs. 6.5%, 9.7%, or 5.0%: p = 0.0026), and no treatment at recurrence (29.3% vs. 9.7%, 9.7%, or 5.0%: p = 0.0115). These results indicate that the tumor markers AFP and DCP are significant prognostic factors for recurrent HCC, and their monitoring is essential for improving the prognosis after recurrence.

PubMed Disclaimer

Similar articles

• The tumor marker score is an independent predictor of survival in patients with recurrent hepatocellular carcinoma.
  Okamura Y, Ashida R, Ito T, Sugiura T, Mori K, Uesaka K. Okamura Y, et al. Surg Today. 2015 Dec;45(12):1513-20. doi: 10.1007/s00595-014-1102-2. Epub 2014 Dec 20. Surg Today. 2015. PMID: 25527455
• Prognostic roles of preoperative α-fetoprotein and des-γ-carboxy prothrombin in hepatocellular carcinoma patients.
  Meguro M, Mizuguchi T, Nishidate T, Okita K, Ishii M, Ota S, Ueki T, Akizuki E, Hirata K. Meguro M, et al. World J Gastroenterol. 2015 Apr 28;21(16):4933-45. doi: 10.3748/wjg.v21.i16.4933. World J Gastroenterol. 2015. PMID: 25945007 Free PMC article.
• Post-ablation des-gamma-carboxy prothrombin level predicts prognosis in hepatitis B-related hepatocellular carcinoma.
  Lee S, Rhim H, Kim YS, Kang TW, Song KD. Lee S, et al. Liver Int. 2016 Apr;36(4):580-7. doi: 10.1111/liv.12991. Epub 2015 Nov 18. Liver Int. 2016. PMID: 26503910
• Diagnostic and prognostic value of alpha-fetoprotein, des-γ-carboxy prothrombin and squamous cell carcinoma antigen immunoglobulin M complexes in hepatocellular carcinoma.
  Bertino G, Neri S, Bruno CM, Ardiri AM, Calvagno GS, Malaguarnera M, Toro A, Malaguarnera M, Clementi S, Bertino N, Di Carlo I. Bertino G, et al. Minerva Med. 2011 Oct;102(5):363-71. Minerva Med. 2011. PMID: 22193346 Review.
• Elevated alpha-fetoprotein: differential diagnosis - hepatocellular carcinoma and other disorders.
  Wong RJ, Ahmed A, Gish RG. Wong RJ, et al. Clin Liver Dis. 2015 May;19(2):309-23. doi: 10.1016/j.cld.2015.01.005. Epub 2015 Feb 27. Clin Liver Dis. 2015. PMID: 25921665 Review.

Cited by

• Significant down-regulation of growth hormone receptor expression revealed as a new unfavorable prognostic factor in hepatitis C virus-related hepatocellular carcinoma.
  Lin CC, Liu TW, Yeh ML, Tsai YS, Tsai PC, Huang CF, Huang JF, Chuang WL, Dai CY, Yu ML. Lin CC, et al. Clin Mol Hepatol. 2021 Apr;27(2):313-328. doi: 10.3350/cmh.2020.0247. Epub 2020 Dec 14. Clin Mol Hepatol. 2021. PMID: 33317258 Free PMC article.
• A nomogram for predicting the risk of postoperative recurrence of hepatitis B virus-related hepatocellular carcinoma in patients with high preoperative serum glutamyl transpeptidase.
  Zhang JS, Wang ZH, Guo XG, Zhang J, Ni JS. Zhang JS, et al. J Gastrointest Oncol. 2022 Feb;13(1):298-310. doi: 10.21037/jgo-21-450. J Gastrointest Oncol. 2022. PMID: 35284131 Free PMC article.
• The tumor marker score is an independent predictor of survival in patients with recurrent hepatocellular carcinoma.
  Okamura Y, Ashida R, Ito T, Sugiura T, Mori K, Uesaka K. Okamura Y, et al. Surg Today. 2015 Dec;45(12):1513-20. doi: 10.1007/s00595-014-1102-2. Epub 2014 Dec 20. Surg Today. 2015. PMID: 25527455
• Modified Albumin-Bilirubin Grade and Alpha-Fetoprotein Score (mALF Score) for Predicting the Prognosis of Hepatocellular Carcinoma after Hepatectomy.
  Kaibori M, Yoshii K, Matsui K, Matsushima H, Kosaka H, Yamamoto H, Aoi K, Yamaguchi T, Yoshida K, Hatanaka T, Hiraoka A, Tada T, Kumada T, Sekimoto M. Kaibori M, et al. Cancers (Basel). 2022 Oct 27;14(21):5292. doi: 10.3390/cancers14215292. Cancers (Basel). 2022. PMID: 36358711 Free PMC article.
• Impact of PIVKA-II in diagnosis of hepatocellular carcinoma.
  Zakhary NI, Khodeer SM, Shafik HE, Abdel Malak CA. Zakhary NI, et al. J Adv Res. 2013 Nov;4(6):539-46. doi: 10.1016/j.jare.2012.10.004. Epub 2013 Jan 11. J Adv Res. 2013. PMID: 25685463 Free PMC article.

References

1. 1. Cancer. 1996 May 1;77(9):1781-6 - PubMed
2. 1. World J Surg. 2000 Dec;24(12):1559-65 - PubMed
3. 1. Cancer. 2001 Feb 1;91(3):561-9 - PubMed
4. 1. Ann Surg. 2000 Apr;231(4):544-51 - PubMed
5. 1. Gut. 2000 Jul;47(1):131-6 - PubMed

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Springer
  • Wiley

• Medical

  • MedlinePlus Health Information

• Miscellaneous

  • NCI CPTAC Assay Portal